Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20056291 | 0.88 | RAB9A (0.52) | RAB9AMEN1KMT2ACCR1CCR5 | |
| SCHEMBL15345108 | 0.88 | RAB9A (0.56) | RAB9AMEN1KMT2ACCR1CCR5 | |
| SCHEMBL16385278 | 0.84 | MAPT (0.48) | RAB9AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL7241046 | 0.84 | ALDH1A1 (0.56) | RAB9AMEN1KMT2ACCR1CCR5 | |
| SCHEMBL21290152 | 0.81 | DYRK1A (0.57) | RAB9AMEN1KMT2ACCR1CCR5 | |
| SCHEMBL27842922 | 0.80 | CCR1 (0.61) | RAB9AMEN1KMT2ACCR1CCR5 | |
| SCHEMBL10207982 | 0.80 | NPC1 (0.54) | RAB9AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL8418986 | 0.80 | RAB9A (0.48) | RAB9AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL16385234 | 0.79 | RAB9A (0.53) | RAB9AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL16385406 | 0.79 | KDM4E (0.52) | RAB9AMEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020715-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| EP-3020715-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| EP-3020715-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | Sumitomo Chemical Company Limited (JP) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015005499-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | 住友化学株式会社 (JP) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SOD1, UQCRB, MT-CO1 | RAB9A 533/4885MEN1 3183/4885KMT2A 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.